1-20 of 33
Graciela M. Nogueras-Gonzalez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Sankalp Arora, Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Musa Yilmaz, Joseph E. Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Guilin Tang, Koji Sasaki, Gautam Borthakur, Joie Alvarez, Sherry Pierce, Graciela M. Nogueras González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Farhad Ravandi, Guillermo Garcia-Manero, Hussein A. Abbas, Naval Daver
Journal: Blood
Blood (2024) 144 (Supplement 1): 735.
https://doi.org/10.1182/blood-2024-203706
Published: 2024
Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Alexandre Bazinet, Tapan M. Kadia, Nicholas Short, Gautam Borthakur, Sa A Wang, Sanam Loghavi, Jeffrey L. Jorgensen, Keyur P. Patel, Courtney D. DiNardo, Naval Daver, Yesid Alvarado, Fadi Haddad, Sherry A. Pierce, Graciela M. Nogueras González, Abhishek Maiti, Michael Andreeff, Elias Jabbour, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2267–2269.
https://doi.org/10.1182/blood-2022-162892
Published: 2022
Journal Articles

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Jayastu Senapati, Abhishek Maiti, Sanam Loghavi, Tapan M. Kadia, Courtney D. DiNardo, Naveen Pemmaraju, Elias Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Ghayas C. Issa, Michael Andreeff, Hussein A Abbas, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood
Blood (2022) 140 (Supplement 1): 141–144.
https://doi.org/10.1182/blood-2022-170188
Published: 2022
Journal Articles

Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents

Guillermo Montalban-Bravo, Elias J. Jabbour, Zeev E. Estrov, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Graciela M. Nogueras González, Xiao Qin Dong, Stefan Faderl, Heather Schneider, Rosmy B. John, Meghan Anne Meyer, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 3674.
https://doi.org/10.1182/blood-2021-151493
Published: 2021
Journal Articles

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Naval Daver, Marina Konopleva, Abhishek Maiti, Tapan M. Kadia, Courtney D. DiNardo, Sanam Loghavi, Naveen Pemmaraju, Elias J. Jabbour, Guillermo Montalban-Bravo, Guilin Tang, Koji Sasaki, Gautam Borthakur, Musa Yilmaz, Joie Alvarez, Michelle Golez, Sherry A. Pierce, Graciela M. Nogueras González, Jing Ning, Hussein A Abbas, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 371.
https://doi.org/10.1182/blood-2021-153638
Published: 2021
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-139942
Published: 2020
Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Patrick K Reville, MD, Graciela M. Nogueras González, MPH, Farhad Ravandi, MBBS, Koji Sasaki, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141837
Published: 2020
Journal Articles

Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients

Preetesh Jain, MBBS,MDDM,PhD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Chi Young Ok, MD, Lucy Navsaria, MB BCh BAO, Maria Badillo, MSN, RN, OCN, CCRP, Wendy Chen, Yijing Li, MS, Yuxuan Che, Yang Liu, PhD, Onyeka Oriabure, Graciela M. Nogueras González, MPH, Jason Westin, MD, Loretta J. Nastoupil, MD, Sairah Ahmed, MD, Ranjit Nair, Selvi Thirumurthi, Shaoying Li, MD, Rashmi Kanagal-Shamanna, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Michael Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
https://doi.org/10.1182/blood-2020-137473
Published: 2020
Journal Articles

Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Lucy Navsaria, MB BCh BAO, Chi Young Ok, MD, Holly Hill, Dayoung Jung, Graciela M. Nogueras González, MPH, Hun Ju Lee, MD, Ranjit Nair, Sairah Ahmed, MD, Raphael Eric Steiner, MD, Guilin Tang, MD, Shaoying Li, MD, Keyur Patel, MD PhD, Selvi Thirumurthi, Pan Tinsu, Guofang Xu, MD, Francisco Vega, MDPhD, Christopher Flowers, MDMS, Michael Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-136978
Published: 2020
Journal Articles

Prognostic Impact of Measurable Residual Disease on Survival in Acute Myeloid Leukemia: A Meta-Analysis of 81 Studies

Nicholas J. Short, MD, Shouhao Zhou, Chenqi Fu, Donald Berry, MD PhD, Roland P Walter, MDPhD, Sylvie D Freeman, Christopher S. Hourigan, MDDPhil, Xuelin Huang, PhD, Graciela M. Nogueras González, MPH, Hyunsoo Hwang, Xinyue Qi, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-135939
Published: 2020
Journal Articles

Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial

Michael Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Yixin Yao, PhD, Yang Liu, PhD, Shuangtao Zhao, PhD, Holly Hill, Omar Moghrabi, Hun Ju Lee, MD, Felipe Samaniego, MD, Jason Westin, MD, Loretta J. Nastoupil, MD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Wendy Chen, Onyeka Oriabure, Yuxuan Che, Yijing Li, MS, Lei Feng, MS, Graciela M. Nogueras González, MPH, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Francisco Vega, MDPhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, MSN, RN, OCN, CCRP, Christopher Flowers, MDMS, Linghua Wang, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-137259
Published: 2020
Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1720.
https://doi.org/10.1182/blood-2019-130155
Published: 2019
Journal Articles

Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients

Preetesh Jain, MBBS,MDDM,PhD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Gonzalez-Pagan Omarya, Lucy Navsaria, MB BCh BAO, Graciela M. Nogueras González, MPH, Shaojun Zhang, PhD, Guangchun Han, Ahmad Ghorab, Prajwal Boddu, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Krystle Nomie, PhD, Changying Jiang, PhD, Luis Fayad, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Sairah Ahmed, MD, Swaminathan P. Iyer, MD, Richard E. Champlin, MD, Sattva S Neelapu, MD, Jorge Enrique Romaguera, MD, Nathan H. Fowler, MD, Guilin Tang, MD, Shaoying Li, MD, Keyur Patel, MD PhD, Selvi Thirumurthi, Pan Tinsu, Guofang Xu, MD, Linghua Wang, PhD, Michael L. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1526.
https://doi.org/10.1182/blood-2019-125936
Published: 2019
Journal Articles

Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet

Hycienth O Ahaneku, MD MPH, PhD, Hagop M. Kantarjian, MD, Graciela M. Nogueras González, MPH, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Marina Y Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ghayas C. Issa, MD, Elias Jabbour, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2930.
https://doi.org/10.1182/blood-2019-129108
Published: 2019
Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, MD, Preetesh Jain, MBBS,MDDM,PhD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Felipe Samaniego, MD, Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Wendy Chen, Krystle Nomie, PhD, Shaojun Zhang, PhD, Omar Moghrabi, Shuangtao Zhao, PhD, Rashmi Kanagal-Shamanna, MD, Chi Young Ok, MD, Onyeka Oriabure, Graciela M. Nogueras González, MPH, Dayoung Jung, Lucy Navsaria, MB BCh BAO, Ann Uy, Archie Pedersen, Liang Zhang, MD PhD, Changying Jiang, PhD, Feng Lei, MS, Yixin Yao, PhD, Guofang Xu, MD, Nicolaus Wagner-Bartak, MD, Selvi Thirumurthi, David Santos, Guilin Tang, MD, Keyur Patel, MD PhD, C. Cameron Yin, MD PhD, Michelle Avellaneda, Maria Badillo, Luis Fayad, MD, Sattva S Neelapu, MD, Nathan H. Fowler, MD, Jorge Enrique Romaguera, MD, Linghua Wang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3987.
https://doi.org/10.1182/blood-2019-126044
Published: 2019
Journal Articles

Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Jan A. Burger, Mariela Sivina, Nitin Jain, Ekaterina Kim, Tapan Kadia, Zeev Estrov, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Jeffrey Jorgensen, Jianling Li, Mei Cheng, Fong Clow, Maro Ohanian, Michael Andreeff, Thomas Mathew, Philip Thompson, Hagop Kantarjian, Susan O’Brien, William G. Wierda, Alessandra Ferrajoli, Michael J. Keating
Journal: Blood
Blood (2019) 133 (10): 1011–1019.
https://doi.org/10.1182/blood-2018-10-879429
Published: 2019
Includes: Supplemental data
Journal Articles

The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Rita Assi, MD, Kiran Naqvi, MD MPH, Ana Alfonso Pierola, MD PhD, Musa Yilmaz, MD, Nicholas J Short, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MD MSc, Graciela M. Nogueras González, MPH, Yasmin Abaza, MD, KC Devendra, MD, Kamal Chamoun, MD, Kenichi Sakurai, MD, Keyur P. Patel, MBBS, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4359.
https://doi.org/10.1182/blood-2018-99-116240
Published: 2018
Journal Articles

PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition

Ivo Veletic, MD, Taghi Manshouri, PhD, Graciela M. Nogueras González, MPH, Sanja Prijic, PhD, Joseph E. Bove, IV, Ying Zhang, MD MS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5487.
https://doi.org/10.1182/blood-2018-99-119428
Published: 2018
Journal Articles

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MD MSc, Michelle Velasquez, RN, Mary Kelly, Jing Ning, PhD, Graciela M. Nogueras González, MPH, Sherry A. Pierce, BSN, BA, Dan Gombos, MD, Zeev E. Estrov, MD, Steven M. Kornblau, MD, Weiguo Zhang, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1441.
https://doi.org/10.1182/blood-2018-99-118028
Published: 2018
Journal Articles

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Sreyashi Basu, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Marina Y. Konopleva, MD PhD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Rita Assi, MD, Sherry A. Pierce, BSN, BA, Yesid Alvarado, MD, Zeev E. Estrov, MD, Naveen Pemmaraju, MD, Koichi Takahashi, MD, Jing Ning, PhD, Graciela M. Nogueras González, MPH, Steven M. Kornblau, MD, Mansour Alfayez, MD, Jairo Matthews, BA, Wilmer Flores, Jorge Blando, DVM, James P Allison, PhD, Padmanee Sharma, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 906.
https://doi.org/10.1182/blood-2018-99-120157
Published: 2018